Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price boosted by Jefferies Group from $251.00 to $274.00 in a report issued on Wednesday, Stock Ratings Network reports. They currently have a hold rating on the stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 2.20% during mid-day trading on Wednesday, hitting $283.07. 747,155 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $136.13 and a 52 week high of $319.83. The stock’s 50-day moving average is $298.2 and its 200-day moving average is $262.9. The company has a market cap of $27.656 billion and a P/E ratio of 36.62.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $1.48. The company had revenue of $597.00 million for the quarter, compared to the consensus estimate of $501.93 million. During the same quarter in the prior year, the company posted $1.89 earnings per share. The company’s quarterly revenue was up 39.6% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $3.82 EPS for the current fiscal year.
A number of other firms have also recently commented on REGN. Analysts at Credit Suisse raised their price target on shares of Regeneron Pharmaceuticals from $275.00 to $340.00 in a research note to investors on Wednesday. They now have an outperform rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Regeneron Pharmaceuticals from $216.00 to $225.00 in a research note to investors on Wednesday. They now have a market perform rating on the stock. Finally, analysts at BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $325.00 to $331.00 in a research note to investors on Wednesday. They now have an outperform rating on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals has a consensus rating of Buy and an average price target of $280.25.
In other Regeneron Pharmaceuticals news, Director Joseph Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock on the open market in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $300.74, for a total value of $300,740.00. Following the completion of the sale, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $902,220. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.